Big Pharma
29 April 2025 EWHC ruling discusses application of EPO case law regarding lack of plausibility and lack of technical contribution | Court had earlier overturned a first-instance decision allowing an injunction against Glenmark’s diabetes generic | AstraZeneca intends to appeal.
10 April 2025
Latest Features
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP.
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.
Europe
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
More News
10 April 2025 The Düsseldorf court’s decision offers an instructive perspective on the legal nature of patent pledges as well as a reminder that it is risky to rely solely on informal public declarations, say Ina vom Feld and Maximilian Kücking of Herbert Smith Freehills.
3 April 2025 The IP specialist bypassed vendors and turned to its own ‘tech geeks’ to create an in-house AI solution for drafting patent applications. LSIPR meets the attorney coders doing it for themselves.
3 April 2025 Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing competition and patent expiration increase urgency for Lilly | New Jersey and Delaware stores accused of selling unapproved tirzepatide-based products.
1 April 2025 MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.
27 March 2025 Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.
27 March 2025 Advocate general recommends upholding €60.48 million fine against Teva and Cephalon for anti-competitive modafinil settlement.
13 March 2025 As IP professionals wait for agency cutbacks to be felt down the chain, the advice is to stay informed, manage budgets wisely, and use a mix of protections to weather any disruption, finds Marisa Woutersen.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox